Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis

BACKGROUND: A Phase I, single-center investigation found that 8 weeks of antimycobacterial therapy improved sarcoidosis FVC. Safety and efficacy assessments have not been performed in a multicenter cohort. RESEARCH QUESTION: The objective of this study was to determine the safety and efficacy of ant...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chest
Hauptverfasser: Drake, Wonder P., Culver, Daniel A., Baughman, Robert P., Judson, Marc A., Crouser, Elliott D., James, W. Ennis, Ayers, Gregory D., Ding, Tan, Abel, Kenny, Green, Abena, Kerrigan, Amy, Sesay, Ahmed, Bernard, Gordon R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American College of Chest Physicians 2021
Schlagworte:
Diffuse Lung Disease: Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8129732/
https://ncbi.nlm.nih.gov/pubmed/33387486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chest.2020.12.027
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge